Medtronic Stock Today, November 26, 2025: MDT Hits Fresh 52‑Week High on Earnings Momentum and Analyst Upgrades

Published: November 26, 2025 – Ticker: NYSE: MDT

Medtronic plc’s share price is pushing to new 52‑week highs as investors digest last week’s strong Q2 FY26 results, a fresh SEC filing, renewed institutional buying and a wave of bullish analyst target hikes. Together, they are underpinning one of the strongest runs Medtronic stock has seen in years.

Medtronic stock price today: MDT near new 52‑week high

As of the latest available trading data, Medtronic stock is changing hands at around $105.35, up a little over 2% from the prior close. The shares have traded between $102.52 and $105.59 in the most recent session on robust volume of roughly 9.3 million shares.

In the early hours of November 26, 2025, an Investing.com company‑news update confirmed that Medtronic hit a fresh 52‑week high of $105.25, marking a milestone in the stock’s recovery. The article highlighted that the share price has climbed about 24% over the past 12 months, with gains of more than 30% year‑to‑date and nearly 30% over the last six months, underscoring powerful medium‑term momentum. ^[1]

At this level, MDT is trading above its recent 50‑day and 200‑day moving averages, reinforcing the view that the prevailing trend is decisively bullish. MarketBeat’s latest institutional‑flow summary notes a 1‑year high just above $102, meaning today’s move has pushed the stock well beyond the previous range. ^[2]

Today’s key news: new high, fresh 10‑Q and options buzz

Several pieces of current news around November 25–26, 2025 are shaping Medtronic’s trading narrative today:

1. 52‑week high confirms the breakout

The Investing.com piece titled “Medtronic stock hits 52-week high at 105.25 USD” (published November 26, 2025 at 04:06 a.m.) framed the new high as a sign of investors’ confidence in Medtronic’s fundamentals and balance‑sheet strength.
The report also cited data from InvestingPro that assigns Medtronic a “great” financial‑health score and emphasized the company’s decades‑long track record of paying (and raising) dividends. ^[3]

In plain terms: the market is rewarding Medtronic for delivering growth and reliability at the same time—a combination investors don’t get very often in large‑cap healthcare.

2. Fresh 10‑Q filing fills in the details behind Q2

On November 25, 2025, Medtronic filed its latest Form 10‑Q for the quarter ended October 24, 2025, and that filing is still being actively cited in news coverage today. A detailed summary on StockTitan highlights: ^[4]

Net sales climbed to about $8.96 billion from $8.40 billion a year earlier – roughly 6.6% growth.
Net income attributable to Medtronic rose to about $1.37 billion, up from $1.27 billion.
Diluted EPS improved to $1.07 versus $0.99 in the prior‑year quarter.
For the first six months of FY26, net sales reached $17.54 billion compared with $16.32 billion a year ago, showing that top‑line acceleration isn’t a one‑off.
Operating cash flow of about $2.0 billion supported both $1.82 billion in dividends and roughly $495 million of share repurchases in the first half of the fiscal year.
On the balance sheet, the company reported over $8.3 billion in cash and investments, total assets of about $91 billion, and total equity close to $49 billion, alongside long‑term debt of roughly $27.7 billion including newly issued notes, plus $1.4 billion of commercial paper.

The 10‑Q confirms what the earnings press release suggested: Medtronic is growing, cash‑generative, and still returning a large amount of capital to shareholders while investing for the future.

3. Options strategists lean bullish

An options‑focused article from Investor’s Business Daily (IBD), published today, points out that: ^[5]

Medtronic’s Relative Strength Rating has improved sharply as the stock hit its 52‑week high.
Implied volatility remains relatively low, making debit call spreads (such as a March $105/$115 bull call spread) an appealing way for some traders to express a bullish view with defined risk.

While this is aimed at active options traders rather than long‑term holders, it underscores that the recent rally is attracting attention across different parts of the market, including derivatives desks.

Earnings momentum: Q2 FY26 results still driving the story

Much of today’s enthusiasm can be traced back to Medtronic’s Q2 FY26 earnings, released on November 18, 2025. In its official press release, the company reported: ^[6]

Revenue of about $9.0 billion, up 6.6% as reported and 5.5% organically, beating internal guidance by roughly 75 basis points at the midpoint.
GAAP diluted EPS of $1.07, up around 8% year‑over‑year.
Non‑GAAP diluted EPS of $1.36, also up about 8%, and ahead of management’s guidance.
A guidance hike for fiscal 2026 to 5.5% organic revenue growth and $5.62–$5.66 in adjusted EPS.

Operationally, the key growth drivers were:

Cardiovascular portfolio: strongest revenue growth in more than a decade (excluding the unusual pandemic period).
Cardiac Ablation Solutions: revenue up 71%, including 128% growth in the U.S., driven by Medtronic’s pulsed field ablation (PFA) technology.
Regulatory & reimbursement wins:
- A broad National Coverage Determination (NCD) from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system in uncontrolled hypertension, opening a U.S. addressable market estimated at 18 million people.
- FDA approval of the Altaviva device for urge urinary incontinence, a condition affecting more than 16 million people in the U.S.

For growth‑oriented investors, these details matter: they show that Medtronic is not just cutting costs or buying back shares to grow EPS; it’s leaning on genuinely expanding markets in cardiovascular, hypertension and urology.

Institutional investors continue to build positions

A new MarketBeat instant alert, dated November 25, 2025, reports that Longfellow Investment Management Co. LLC raised its Medtronic stake by 48.1% in the second quarter. Longfellow added 3,362 shares, bringing its holdings to 10,354 shares valued at roughly $903,000 at the time of the filing. ^[7]

The same report notes that some of the largest global asset managers have also been adding to positions:

Vanguard Group now holds about 126.9 million shares.
Geode Capital, BNY Mellon, Deutsche Bank, and Invesco have all incrementally increased their exposure. ^[8]

Depending on the data source, estimates suggest that over 80% of Medtronic’s float is held by institutions, which is typical for a mature, large‑cap healthcare leader but still significant—it means professional investors are heavily involved in setting the share price. ^[9]

Institutional accumulation, combined with rising price targets, is a big part of why MDT is attracting attention on screens and in Google Discover feeds today.

Analyst sentiment: target hikes and a broad “Buy” consensus

Over the past week, several major sell‑side firms have updated their views on Medtronic, and those calls remain highly relevant to today’s trading:

On November 19, 2025, RBC Capital reaffirmed an “Outperform” rating and raised its price target from $111 to $118, implying continued upside from recent levels. ^[10]
The same day, Morgan Stanley reiterated an “Overweight” rating and lifted its target from $107 to $117, a roughly 9% increase in its 12‑month view. ^[11]

Both notes highlighted a trend that’s become hard to ignore: most recent analyst revisions on Medtronic have been upward, not downward, as the company has returned to consistent mid‑single‑digit organic growth.

According to StockAnalysis, which aggregates Wall Street estimates, Medtronic currently carries an average “Buy” rating from around 18 analysts, with a 12‑month consensus target price near $108.63—a modest premium to the latest trading level, but below the more optimistic targets from RBC and Morgan Stanley. ^[12]

In short, the average view is mildly bullish, while several high‑profile analysts clearly see more upside than the consensus.

Dividend strength and cash returns remain a core part of the story

Income investors watching MDT today will care less about options spreads and more about the dividend:

Medtronic declared a quarterly dividend of $0.71 per share for Q2 FY26, payable October 17, 2025 to shareholders of record on September 26, 2025. ^[13]
That payout is in line with the increase announced earlier in 2025 and contributes to an annual dividend of roughly $2.84 per share, equating to a yield of about 2.7% at current prices. ^[14]
The company has raised its annual dividend for 48 consecutive years, qualifying it as a member of the S&P 500 Dividend Aristocrats index. ^[15]

Combined with ongoing share repurchases highlighted in the 10‑Q, Medtronic continues to position itself as a blend of growth and income—a profile that appeals to many long‑term investors even when broader markets are volatile.

Valuation and risks investors are weighing today

At roughly $105 per share, Medtronic now trades at: ^[16]

A trailing P/E ratio in the high‑20s based on TTM earnings.
A forward P/E in the high‑teens, assuming management meets its FY26 EPS guidance.
A dividend yield around 2.5–3.0%, depending on the exact price at any given moment.

Key upside drivers supporting today’s rally include:

Sustained mid‑single‑digit organic revenue growth for the first time in years. ^[17]
Rapid adoption of new technologies (notably PFA in cardiac ablation). ^[18]
Expanded reimbursement and coverage for renal denervation, which could open a sizable hypertension market over time. ^[19]

However, investors are also monitoring risks, such as:

Integration and execution risk as Medtronic ramps multiple new platforms at once.
Pricing and reimbursement pressures in key markets, especially as more data emerges on renal denervation and other new therapies.
Ongoing regulatory and legal exposure, including periodic product recalls and False Claims Act litigation that is part of the backdrop for large U.S. medtech names. ^[20]

For now, though, the balance of news since the November 18 earnings release clearly skews positive, and that is reflected in the price action around November 26, 2025.

What to watch next for MDT

Looking ahead from today’s vantage point:

Post‑earnings drift: With Q2 numbers out and the 10‑Q filed, investors will be watching whether MDT can hold above the new 52‑week high or whether short‑term profit‑taking sets in. ^[21]
Pipeline and product updates: Any new data or approvals in pulsed field ablation, renal denervation, robotics or diabetes technology could provide additional catalysts. ^[22]
Further analyst revisions: After the RBC and Morgan Stanley target hikes, additional updates from other brokers could nudge consensus higher—or signal that expectations are catching up with reality. ^[23]

For now, November 26, 2025 stands out as a milestone date for Medtronic shareholders: the day the stock definitively broke out to a new 52‑week high, backed by solid fundamentals, robust cash generation, and increasingly constructive Wall Street sentiment.